{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:33:56Z","timestamp":1773358436379,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n \n 18<\/jats:sup>\n F-fluorodeoxyglucose (\n 18<\/jats:sup>\n F-FDG) positron-emission tomography\/computed tomography (PET\/CT) and\n 68<\/jats:sup>\n Ga-prostate-specific membrane antigen (\n 68<\/jats:sup>\n Ga-PSMA) PET\/CT are widely used imaging modalities for the diagnosis and management of prostate cancer. However, comparative data on their performance in evaluating residual disease in treated metastatic prostate cancer remain limited. This study aimed to compare the efficacy of\n 68<\/jats:sup>\n Ga-PSMA-11 and\n 18<\/jats:sup>\n F-FDG PET\/CT in detecting residual lesions after therapy in patients with metastatic prostate cancer.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We retrospectively analyzed 26 metastatic prostate cancer patients who underwent both\n 68<\/jats:sup>\n Ga-PSMA-11 PET\/CT and\n 18<\/jats:sup>\n F-FDG PET\/CT at Nanyang Central Hospital between January 2023 and June 2025.\u00a0A composite reference standard incorporating histopathology (when available) and follow-up contrast-enhanced CT or MRI was used to confirm metastatic lesions. Lesion-based detection rates and tumor-to-background ratios (TBR) were compared between the two tracers.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In post-treatment primary tumors, detection rates were 92% for\n 18<\/jats:sup>\n F-FDG and 100% for\n 68<\/jats:sup>\n Ga-PSMA-11.\n 68<\/jats:sup>\n Ga-PSMA-11 demonstrated significantly higher SUVmax (median 17.08 vs 5.05, IQR 10.76-24.67 vs 3.90-6.38; P &lt; 0.001, r = 0.81) and TBR (median 26.98 vs 4.81, IQR 17.00-38.97 vs 3.72-6.08; P &lt; 0.001, r = 0.85) than\n 18<\/jats:sup>\n F-FDG. For bone metastases, detection rates were 95% and 100%, respectively, with\n 68<\/jats:sup>\n Ga-PSMA-11 again exhibiting superior SUVmax and TBR (8.29 \u00b1 5.02 vs 33.77 \u00b1 23.51, P &lt; 0.001, d = 0.95; 6.56 \u00b1 3.97 vs 33.08 \u00b1 23.03, P &lt; 0.001, d = 1.03). The per-lesion detection rate for lymph node metastases was 91% for\n 18<\/jats:sup>\n F-FDG PET\/CT and 96% for\n 68<\/jats:sup>\n Ga-PSMA-11 PET\/CT. SUVmax and TBR were significantly higher with\n 68<\/jats:sup>\n Ga-PSMA-11 (17.02 (9.40-27.07) vs 4.17 (3.55-5.17), P\u00a0=\u00a00.005, r = 0.80; 26.88 (14.85-42.77) vs 3.96 (3.38-4.93), P\u00a0=\u00a00.002, r = 0.85).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n 68<\/jats:sup>\n Ga-PSMA-11 PET\/CT shows higher tracer avidity and tumor-to-background contrast than\n 18<\/jats:sup>\n F-FDG PET\/CT for detecting residual primary tumors, lymph node, and bone metastases after therapy in metastatic prostate cancer.\n 18<\/jats:sup>\n F-FDG PET\/CT may serve as a complementary modality, and combined use of both tracers could enhance the detection of residual disease in treated patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1713930","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:38:41Z","timestamp":1773319121000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET\/CT"],"prefix":"10.3389","volume":"16","author":[{"given":"Tengfei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Computed Tomography (CT) Imaging, Nanyang Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Computed Tomography (CT) Imaging, Nanyang Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Computed Tomography (CT) Imaging, Nanyang Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Computed Tomography (CT) Imaging, Nanyang Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215360","article-title":"Molecular imaging in primary staging of prostate cancer patients: Current aspects and future trends","volume":"13","author":"Manafi-Farid","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040805","article-title":"Tissue-based diagnostic biomarkers of aggressive variant prostate cancer: A narrative review","volume":"16","author":"Kouroukli","year":"2024","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.008","article-title":"Years of life lost in metastatic and locally advanced prostate cancer","volume":"8","author":"Falkenbach","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9038-9048","DOI":"10.1097\/JS9.0000000000003269","article-title":"The role of apparent diffusion coefficient values in diagnosing prostate cancer for patients with equivocal PI-RADS 3 lesions: A multicenter retrospective study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07208-z","article-title":"Prospective comparison of 18F-PSMA-1007 PET\/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer","volume":"52","author":"Kivikallio","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683793","article-title":"The Evolving Role of 18F-FDG PET\/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer","volume":"11","author":"Shen","year":"2021","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270077","article-title":"Deep learning for automated measures of SUV and molecular tumor volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 imaging with global threshold regional consensus network","volume":"66","author":"Jackson","year":"2025","journal-title":"J Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2016.07.005","article-title":"PET tracers beyond FDG in prostate cancer","volume":"46","author":"Schuster","year":"2016","journal-title":"Semin Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.210091","article-title":"18 F-Fluciclovine versus PSMA PET imaging in primary tumor detection during initial staging of high-risk prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Yadav","year":"2022","journal-title":"Radiol: Imaging Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","article-title":"Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: A systematic review and meta-analysis","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318252d829","article-title":"Prospective evaluation of 18F-NaF and 18F-FDG PET\/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer","volume":"37","author":"Jadvar","year":"2012","journal-title":"Clin Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","article-title":"Increased prostate cancer glucose metabolism detected by 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in localised Gleason 8\u201310 prostate cancers identifies very high\u2013risk patients for early recurrence and resistance to castration","volume":"5","author":"Lavall\u00e9e","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40644-021-00440-4","article-title":"PET\/CT variants and pitfalls in Malignant melanoma","volume":"22","author":"Aide","year":"2022","journal-title":"Cancer Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031158","article-title":"PSMA-targeting imaging and theranostic agents-current status and future perspective","volume":"23","author":"Debnath","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000006004","article-title":"The characteristics of prostate mucinous adenocarcinoma visualized by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET\/CT","volume":"50","author":"Sun","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005607","article-title":"Incidental detection of prostatic lesion on 18 F-FDG PET\/CT and 68 Ga-PSMA-11 PET\/CT leading to diagnosis of second primary prostatic adenocarcinoma in a patient of differentiated thyroid cancer","volume":"50","author":"Gondhane","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study","volume":"50","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.159715","article-title":"Quantification, variability, and reproducibility of basal skeletal muscle glucose uptake in healthy humans using18 F-FDG PET\/CT","volume":"56","author":"Gheysens","year":"2015","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/thno.31970","article-title":"Regularized reconstruction of digital time-of-flight68 Ga-PSMA-11 PET\/CT for the detection of recurrent disease in prostate cancer patients","volume":"9","author":"Lindstr\u00f6m","year":"2019","journal-title":"Theranostics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11050847","article-title":"Impact of the noise penalty factor on quantification in Bayesian penalized likelihood (Q.Clear) reconstructions of 68Ga-PSMA PET\/CT scans","volume":"11","author":"Rijnsdorp","year":"2021","journal-title":"Diagnostics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269971","article-title":"Prognostic value of AI-assisted lesion tracking on end-of-treatment PSMA PET in mCRPC patients treated with 177Lu-PSMA: A retrospective, single-center study","volume":"66","author":"Murthy","year":"2025","journal-title":"J Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07148-8","article-title":"Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: A radio-pathology matching analysis","volume":"52","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05970-y","article-title":"Flare on [18F]PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: Possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004440","article-title":"Altered glucose metabolism postchemotherapy precedes PSMA expression in poorly differentiated prostate cancer","volume":"48","author":"Alabed","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005257","article-title":"Hepatic PSMA-avid postradiation inflammation","volume":"49","author":"Silveira","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07646-9","article-title":"Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer","volume":"53","author":"Chen","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:38:42Z","timestamp":1773319122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1713930"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1713930","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1713930"}}